ALLMedicine™ Hypogammaglobulinemia Center

Sep 11th, 2020 - X-linked agammaglobulinemia (XLA) is characterized by severe or recurrent infections, hypogammaglobulinemia, and circulating B cell deficiency. The frequent pathogens seen in patients with XLA include Streptococcus pneumoniae, Haemophilus influenz...

Sep 1st, 2020 - Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene. We report the safety, tolerability, pharmacokinetics, pharmacodynamics and preli...

Aug 11th, 2020 - Secondary immunodeficiency diseases (SID) caused by hematological malignancies (HMs), stem cell transplant (SCT), and associated therapies are mainly characterized by the presence of hypogammaglobulinemia or antibody production deficits. The autho...

Aug 7th, 2020 - CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell apla...

Jul 24th, 2020 - Adenosine deaminase 2 deficiency (DADA2) is an autoinflammatory disease characterized by inflammatory vasculopathy, early strokes associated often with hypogammaglobulinemia. Pure red cell aplasia, thrombocytopenia, and neutropenia have been repor...

Sep 11th, 2020 - X-linked agammaglobulinemia (XLA) is characterized by severe or recurrent infections, hypogammaglobulinemia, and circulating B cell deficiency. The frequent pathogens seen in patients with XLA include Streptococcus pneumoniae, Haemophilus influenz...

Sep 1st, 2020 - Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene. We report the safety, tolerability, pharmacokinetics, pharmacodynamics and preli...

Aug 11th, 2020 - Secondary immunodeficiency diseases (SID) caused by hematological malignancies (HMs), stem cell transplant (SCT), and associated therapies are mainly characterized by the presence of hypogammaglobulinemia or antibody production deficits. The autho...

Aug 7th, 2020 - CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell apla...

Jul 24th, 2020 - Adenosine deaminase 2 deficiency (DADA2) is an autoinflammatory disease characterized by inflammatory vasculopathy, early strokes associated often with hypogammaglobulinemia. Pure red cell aplasia, thrombocytopenia, and neutropenia have been repor...

Oct 2nd, 2019 - Ocrelizumab Tobias Derfuss, MD, provided data on infection rates in the pivotal phase 3 OPERA and ORATIO double-blind clinical trials combined with their long-term, open-label extensions totaling 288 weeks, or nearly 6 years, of follow-up. Serum I.

Jan 9th, 2019 - Low-dose treatment with plerixafor, a CXC chemokine receptor 4 antagonist, was well tolerated and markedly improved severe presentations of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome in three patients who could not.

Jan 4th, 2019 - SAN DIEGO – Longer-term follow-up of patients treated with CD19-targeted chimeric antigen receptor (CAR) T cells for hematologic malignancies indicates that the altered cells are generally safe, with most late events being mild in nature and possi.

Dec 1st, 2017 - Clinicians are well aware of the increased risk of infection in immunosuppressed patients. But the ecologic balance between infectious agents and the immune system is complex.

May 10th, 2017 - The Immune Deficiency Foundation would like to hear from individuals or families with a definite diagnosis of WHIM syndrome. WHIM is an acronym for some of the characteristic symptoms of the disorder – Warts, Hypogammaglobulinemia, Infections, and.